Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Reports Second Quarter 2018 Financial Results
Helomics Holding Corporation, predicted to generate approximately $3.2 million in revenues by the end of 2018 MINNEAPOLIS , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New ‘HelomicsDiscover’ Program to Drive Forward the Next Generation of Precision Cancer Therapies
MINNEAPOLIS , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML
Toggle Summary Precision Therapeutics Investee, Helomics Corporation, Launches Precision Oncology Insights Platform
MINNEAPOLIS , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation , which has a definitive
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on August 14, 2018
MINNEAPOLIS , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML
Toggle Summary Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange
MINNEAPOLIS , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has received confirmation from the Börse- Stuttgart Stock Exchange (the
View HTML
Toggle Summary Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office
View HTML
Toggle Summary Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation
MINNEAPOLIS , June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that it has signed a definitive merger agreement with
View HTML
Toggle Summary Precision Therapeutics Launches New Website
MINNEAPOLIS , May 31, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has launched a new website:
View HTML
Toggle Summary Precision Therapeutics Reports First Quarter 2018 Financial Results
MINNEAPOLIS , May 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three months ended March 31, 2018 and
View HTML
Toggle Summary Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018
MINNEAPOLIS , May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery and producer of the FDA -approved STREAMWAY® System for automated,
View HTML